Insider Selling: Liquidia Co. (NASDAQ:LQDA) CEO Sells 22,343 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 22,343 shares of the business’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the sale, the chief executive officer now directly owns 1,019,177 shares of the company’s stock, valued at $12,005,905.06. This represents a 2.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Liquidia Price Performance

Shares of LQDA traded down $0.40 during mid-day trading on Tuesday, reaching $11.36. 552,977 shares of the company’s stock traded hands, compared to its average volume of 728,753. The stock has a market cap of $961.48 million, a P/E ratio of -6.97 and a beta of 0.23. The stock’s 50-day moving average is $11.18 and its two-hundred day moving average is $11.02. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.99.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in shares of Liquidia by 855.3% during the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock valued at $2,354,000 after buying an additional 210,753 shares during the last quarter. Barclays PLC grew its stake in shares of Liquidia by 265.0% during the third quarter. Barclays PLC now owns 99,984 shares of the company’s stock valued at $999,000 after buying an additional 72,591 shares during the last quarter. Anson Funds Management LP bought a new position in shares of Liquidia during the third quarter valued at approximately $1,764,000. XTX Topco Ltd bought a new position in shares of Liquidia during the third quarter valued at approximately $323,000. Finally, Wellington Management Group LLP grew its stake in Liquidia by 12.5% in the third quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock worth $1,799,000 after purchasing an additional 19,932 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on LQDA shares. Wells Fargo & Company started coverage on Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Scotiabank assumed coverage on Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Lifesci Capital assumed coverage on Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Liquidia in a research report on Thursday, January 9th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).